By Connor Hart
Shares of Tonix Pharmaceuticals Holding fell after the company logged lower sales and another net loss in the fourth quarter.
The stock declined 6.9%, to $19.12, in after-hours trading Tuesday. Shares, which have lost more than 98% of their value in the past year, have surged 87% in the past month.
The biopharmaceutical company narrowed its fourth-quarter net loss to $22.1 million from $27.3 million a year earlier.
During the same period, net product revenue fell to $2.6 million from $3.8 million.
Research and development expenses fell year over year on fewer clinical trials and pipeline prioritization efforts, though operating expenses rose due to an increase in financial reporting expenses, sales and marketing, and professional fees, the company said.
Chief Executive Seth Lederman said he is optimistic about the year ahead, citing the pending approval of its drug for the management of fibromyalgia and the continued development of its pipeline.
"With commercial preparations under way, we believe we are well positioned to launch TNX-102 SL for the management of fibromyalgia in the fourth quarter of this year, if approved by the U.S. Food and Drug Administration," he said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
March 18, 2025 18:22 ET (22:22 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。